EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
7:00am - 8:00am 60 mins
Info
Continental Breakfast – Hilton Union Square

Grand Ballroom

7:00am - 6:00pm 660 mins
Info
Registration Open – Hilton Union Square

Plaza A, Lobby Level

Please note: The registration desk will be open all day.

8:00am - 9:00am 60 mins
Info
The microbiome: Beyond the gut – Hilton Union Square
  • Moderator Joseph Gulfo - Executive Director, The Lewis Center for Healthcare Innovation and Technology
  • Panelist Thomas Hallam - CEO, Leading BioSciences
  • Panelist Arpita Maiti - Senior Director, External Science & Innovation (ES&I), Inflammation and Immunology and Microbiome, Worldwide Research and Development, Pfizer, Inc.
  • Panelist Glenn Nedwin - CEO and President, Second Genome

Imperial Ballroom

In recent years, the bacterial communities living in and on our bodies have captivated scientists and the public alike. The gut microbiome has been tied to diverse functions and linked to both health and disease. Researchers now know that the gastrointestinal tract is just one of the many microbial homes on the human body and has a direct and measurable influence on both the central nervous and immune system. Even sites once considered sterile revealing themselves to be hotbeds of diversity with potential for addressing therapeutic needs.

8:00am - 6:00pm 600 mins
Info
One-to-one meetings – Hilton Union Square

Grand Ballroom

Please note: One-to-one meetings will take place all day depending on your partnering schedule.

8:00am - 9:05am 65 mins
Info
Next generation CARs and other cell-based immunotherapies – Parc 55
  • Speaker Janet Lynch Lambert - CEO, Alliance for Regenerative Medicine
  • Speaker Robet Preti - Chairman, Alliance for Regenerative Medicine; President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector, Hitachi Chemical Advanced Therapeutics Solutions
  • Chair Morrie Ruffin - Managing Partner, Adjuvant Partners; Co-Founder and Senior Advisor, Alliance for Regenerative Medicine
  • Panelist Bob Azelby - Executive VP, Chief Commercial Officer, Juno Therapeutics
  • Panelist Manuel Litchman - President, CEO and Director, Mustang Bio
  • Panelist James Noble - CEO, Adaptimmune
  • Panelist Pascal Touchon - Senior VP and Global Head, Cell and Gene, Novartis Oncology
  • Panelist Scott Wolchko - President and CEO, Fate Therapeutics

Parc 55, Level 4, Cyril Magnin Ballroom

8:00 - 8:20am      Introduction and Industry Update

8:20 - 9:05am      Next generation CARs and other cell-based immunotherapies


8:30am - 12:00pm 210 mins
Info
Company Presentations – Hilton Union Square

Yosemite A–C; Franciscan A–D

9:00am - 10:00am 60 mins
Info
Entering the Golden Age of dermatology: It’s more than skin deep – Hilton Union Square
  • Moderator Jennifer Friel Goldstein - Market Manager, Silicon Valley Bank
  • Panelist Weston Daniel - Director, Program Management, Exicure, Inc.
  • Panelist Alan Dunton - Senior VP of Research, Development and Regulatory Affairs, Purdue Pharma L.P.
  • Panelist Jennifer Good - President and CEO, Trevi Therapeutics
  • Panelist Shelley Hartman - CEO, Aegle Therapeutics Corporation
  • Panelist Mark Wilson - Co-Founder and CEO, MatriSys Bioscience, Inc.

Imperial Ballroom

Medical dermatology has entered a new and innovative era that goes beyond reformulations of existing therapies and is seeing the emergence of new companies focused on improving the care of patients whose skin diseases have substantial systemic consequences. In fact, as we see a number of emerging companies in this space focused on different therapeutic approaches,  with different modalities and delivery methods, one can say that we are entering the golden age of dermatology—an area that has seen few developments in decades.

9:05am - 9:50am 45 mins
Info
Gene Therapy: The outlook in 2018 – Parc 55
  • Chair Martha Rook - Head, Gene Editing and Novel Modalities, MilliporeSigma
  • Panelist Bill Lundberg - CSO, CRISPR Therapeutics
  • Panelist Sandy Macrae - President and CEO, Sangamo Therapeutics
  • Panelist Geoff Nichol - Senior VP, Global Clinical Development and Chief Medical Officer, BioMarin Pharmaceutical
  • Panelist Amber Salzman - President and CEO, Adverum Biotechnologies

Parc 55, Level 4, Cyril Magnin Ballroom



12:00pm - 1:45pm 105 mins
Info
Lunch Plenary: The future of biotechnology and life sciences sector: Are we at a tipping point? – Hilton Union Square
  • Moderator Sara Radcliffe - President and CEO, California Life Sciences Association (CLSA)
  • Panelist Ron Cohen - President and CEO, Acorda Therapeutics, Inc.
  • Panelist Jim Greenwood - President and CEO, Biotechnology Innovation Organization (BIO)
  • Panelist Rachel King - CEO, GlycoMimetics, Inc.
  • Panelist Paul Mignon - President and Global Head, Selling Solutions, Syneos Health
  • Panelist Lesley Stolz - Head, JLABS California, JLABS @SSF

Imperial Ballroom

The biopharmaceutical industry is often criticized for putting profit above patient welfare. But scientific advances are now leading to a surge in breakthrough medicines that should remind people of the pivotal role the industry has always played in improving the length and quality of patient lives. The promise of this surge in scientific innovation, however, won’t be fully realized unless it can be matched with innovation in how drug companies bring products to market—with a focus on increasing efficiency and speed while reducing costs.
 
This is critically important because unlike any previous time in history, stakeholders in the healthcare ecosystem—patients, providers, intermediaries, and industry— are reimagining how health care will be delivered in the future. And this requires a serious rethinking of current business and operational models to come up with something better suited to the future marketplace. Where does the biopharmaceutical industry go from here?

1:45pm - 5:30pm 225 mins
Info
Company Presentations – Hilton Union Square

Yosemite A–C; Franciscan A–D

3:30pm - 4:30pm 60 mins
Info
The impact of new leadership and new initiatives at FDA — Hilton Union Square
  • Moderator Philip Katz - Partner, Head of FDA Pharmaceutical and Biotechnology Practice, Hogan Lovells
  • Panelist Nancy Bradish Myers - President, Catalyst Healthcare Consulting, Inc.
  • Panelist David Horowitz - Partner, Hogan Lovells (formerly Deputy General Counsel at HHS and Head of the Office of Compliance for Drugs at FDA)
  • Panelist John Jenkins - Principal, Greenleaf Health (formerly Director, Office of New Drugs at FDA)
  • Panelist Gayatri Rao - Outgoing Director, Office of Orphan Products Development, FDA

Imperial Ballroom

It’s not just a new Administration, but also the organic evolution of FDA. This panel of veterans who’ve worked for, with, and across the table from FDA will discuss how things are changing and how they’re staying the same. Topics include the impact of Executive Branch and Congressional politics on FDA, initiatives to address the cost and predictability of drug development and review, risk-based approaches to regulation, and keeping pace with scientific and technological advances.

4:30pm - 5:15pm 45 mins
Info
The public markets and biotech: What to expect in 2018 – Hilton Union Square
  • Moderator Barbara Ryan - Founder, Barbara Ryan Advisors
  • Panelist Gabriel P. Cavazos - Managing Director, Investment Banking, Leerink Partners LLC
  • Panelist Asthika Goonewardene - Senior Biotechnology Analyst, Bloomberg Intelligence
  • Panelist Kris Jenner - Partner, Rock Springs Capital
  • Panelist John Nolan - Managing Director, WBB Asset Management
  • Panelist Josh Scheinfeld - Managing Member, Lincoln Park Capital, LLC

Imperial Ballroom

Overall, the biotechnology sector performed well in 2017 and, according to various observers of this space, there are many reasons to expect good performance in 2018. Will the IPO market continue to be robust? Will we see a pick-up in M&A activity? Will new money continue to flow into this space?

Showing of Streams